
ETON Stock Forecast & Price Target
ETON Analyst Ratings
Bulls say
Eton Pharmaceuticals is experiencing significant growth, with a projected 20% year-over-year revenue increase anticipated for 2024, reaching $38.1 million, and a subsequent dramatic growth forecast of 170% to $103.7 million in 2025. The company is also strategically expanding its product pipeline, with expectations for additional revenue from new product launches, including Amglidia, projected to generate $4.2 million in 2027 and increasing to $16.0 million by 2032, pending FDA approval. Furthermore, Eton's management is effectively executing its portfolio expansion strategy, which has led to upward revisions in revenue expectations based on anticipated pricing increases.
Bears say
Eton Pharmaceuticals Inc. is set to incur significant costs, totaling $30.7 million in upfront payments for recent acquisitions, which raises concerns about cash flow management and financial stability. Additionally, the company is facing competitive pressure as management indicates that the acquired products, Increlex and Galzin, are priced lower than rival drugs, potentially impacting revenue generation. This combination of high acquisition costs and pricing competition may adversely affect Eton's profitability and market position moving forward.
This aggregate rating is based on analysts' research of Eton Pharmaceuticals Inc and is not a guaranteed prediction by Public.com or investment advice.
ETON Analyst Forecast & Price Prediction
Start investing in ETON
Order type
Buy in
Order amount
Est. shares
0 shares